This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.
CME Academic Highlights
Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment
The use of second-generation antipsychotics has not eliminated tardive dyskinesia (TD), and the prevalence of the disorder is higher than commonly realized. The involuntary movements of TD can decrease patients’ quality of life, cause embarrassment, and lead to social withdrawal. Clinicians must evaluate patients taking DRBAs for TD risk factors and regularly screen them for TD using a rating scale. Familiarity with tools and diagnostic criteria will enable clinicians to conduct a differential diagnosis. Once a diagnosis is made, medications approved by the US Food and Drug Administration can be used to treat the condition. These medications are effective, but clinicians should be aware of key differences. A baseline assessment and regular follow-up evaluations will allow the clinician to monitor the patient’s progress and make adjustments to meet treatment goals.
PDF version of article
Note: To receive credit, you must navigate through the entire online activity. Click link below.
J Clin Psychiatry 2020;81(2):TV18059AH3C
To cite: Citrome LL, Saklad SR. Revisiting tardive dyskinesia: focusing on the basics of identification and treatment. J Clin Psychiatry. 2020;81(2):TV18059AH3C
To share: https://doi.org/10.4088/JCP.TV18059AH3C
From the Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla (Dr Citrome); and the Pharmacotherapy Division, The University of Texas at Austin College of Pharmacy, and Pharmacotherapy Education and Research Center, School of Medicine, Utah Health San Antonio (Dr Saklad).
© Copyright 2020 Physicians Postgraduate Press, Inc.
Quick Links: Bipolar Disorder